Henry Gosebruch joined Galapagos as Founding CEO of SpinCo on April 21, 2025 and became Chief Executive Officer of Galapagos NV on May 12, 2025. He is an executive member and member of our Board of Directors since May 12, 2025. Prior to Galapagos, Henry served as President and CEO of Neumora (NASDAQ: NMRA), a clinical-stage biopharmaceutical company focused on neuroscience. Under his leadership, Neumora advanced multiple clinical programs and built strong development capabilities. Prior to Neumora, he was Executive Vice President and Chief Strategy Officer at AbbVie, where his responsibilities included corporate strategy, alliance management, business development, and M&A, contributing to the company’s significant growth, pipeline expansion and diversification. Before AbbVie, he spent over 20 years at J.P. Morgan, where he was Co-Head of the North American M&A Group. Henry currently serves on the Board of Directors at Acelyrin (NASDAQ: SLRN) and on the Advisory Board of the Life Sciences & Management Program at the University of Pennsylvania
